PEOPLE’S MIND – Candidate vaccine dengue hemorrhagic fever (DBD) Takeda (TAK-003) is reported to be able to prevent disease DBD up to 62 percent.
This was known after going through a series of trials of tetravalent immunization against the disease DBD fase 3 (TIDES Phase 3).
Vice President Dengue Global Program Leader Takeda Pharmaceutical Company Limited (Takeda) Derek Wallace announces that Trial of tetravalent immunization against disease DBD phase 3 involves more than 20,000 healthy children and adolescents aged 4 to 16 years, in endemic countries DBD in the Asian and Latin American regions.
According to him, candidate vaccine TAK-003 is stated to be able to reduce the risk of patient hospitalization by up to 83.6 percent, without the risk of other health problems for the next three years after immunization.
Also Read: Viral Video Landslide in Great Asia Africa Bandung, Manager Tells the Fact
<!–
–
–
– –>
“We are optimistic candidates vaccine TAK-003 can help solve the problem DBD in the world,” he said in a press statement released in Osaka, Japan, Friday, May 28, 2021.
He said that dengue fever is a viral disease that spreads quickly through mosquitoes.
Disease DBD became one of the WHO’s top 10 threats to global health in 2019. The options for preventing this disease are still limited to date.
Also Read: Get to know the hot Patricia Fernandez, ‘World’s Fastest Woman’ Riding a Harley Davidson
– .
